DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
From diarylsulfides to diarylamines: new Ebola virus entry inhibitors with improved metabolic stability
15 p.-7 fig.-4 tab.-1 graph. abst., The persistence of current outbreaks of Ebola virus (EBOV) disease and challenges in the production and administration of approved vaccines and treatments highlight the continuous exploration of new therapeutic alternatives. In this context, this work focuses on optimizing diarylsulfide hits previously identified as EBOV entry inhibitors. Structural modifications resulted in diarylamine derivatives, with confirmed antiviral activity against replicative EBOV and significantly improved metabolic stability compared to diarylsulfides. Using different techniques, the EBOV glycoprotein (EBOV-GP) was identified as the target of these compounds. Residue Y517GP2 is critical for biological activity, while T519GP2, E100GP1, and D522GP2 also contribute to ligand binding. Furthermore, the binding of the derivatives to EBOV-GP has been shown to destabilize the complex with the virus receptor NPC1. In short, a new family of diarylsulfides and diarylamines with antiviral activity against EBOV has been developed, and their mechanism of action has been deciphered, paving the way for future pharmaceutical development., The project leading to these results has received funding from “la Caixa” Foundation under the project code LCF/PR/HR19/52160012. This research was partially supported through ERA-NET-2021-862605 and cofounded by MICIU/AEI/10.13039/501100011033 and FEDER/UE (Grants PCI2021-121939 (C.A.), PID2021-122825OB (C.A.), PID2023-151109OB-I00 (A.C.) and PID2021-122223OB-I00 (C.G.)), Instituto de Salud Carlos III (CIBERINFEC, CIBERNED and FIS PI2100989), and the European Commission Project e-FabRIC: ID: 101137157, HORIZON-HLTH-2023-DISEASE-03-04 and Project Ebola PREP-TBOX, ID 101145709, and HORIZON-JU-GH-EDCTP3-2023-01 to RD. This research work was also funded by the European Commission–NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI+ Salud Global). M.M.-T. holds a predoctoral FPU grant (FPU18/03493) from MICINN., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PCI2021-121939
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-122825OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2023-151109OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-122223OB-I00
,
EC / HE 101137157
,
EC / HE 101145709